301257 Stock Overview
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 301257 from our risk checks.
SMO ClinPlus CO.,LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥43.29 |
52 Week High | CN¥85.61 |
52 Week Low | CN¥33.60 |
Beta | 0 |
1 Month Change | -14.24% |
3 Month Change | -16.91% |
1 Year Change | -34.72% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -42.00% |
Recent News & Updates
Recent updates
Shareholder Returns
301257 | CN Life Sciences | CN Market | |
---|---|---|---|
7D | -3.1% | 2.2% | 1.6% |
1Y | -34.7% | -38.3% | -15.1% |
Return vs Industry: 301257 exceeded the CN Life Sciences industry which returned -38.3% over the past year.
Return vs Market: 301257 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
301257 volatility | |
---|---|
301257 Average Weekly Movement | 10.0% |
Life Sciences Industry Average Movement | 9.6% |
Market Average Movement | 8.8% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 301257's share price has been volatile over the past 3 months.
Volatility Over Time: 301257's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 4,061 | n/a | www.smo-clinplus.com |
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company’s SMO services incudes preliminary model establishment, preliminary plan preparation, initiation of clinical trial sites, on-site implementation, and project management services.
SMO ClinPlus CO.,LTD. Fundamentals Summary
301257 fundamental statistics | |
---|---|
Market cap | CN¥2.65b |
Earnings (TTM) | CN¥135.11m |
Revenue (TTM) | CN¥728.80m |
19.6x
P/E Ratio3.6x
P/S RatioIs 301257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301257 income statement (TTM) | |
---|---|
Revenue | CN¥728.80m |
Cost of Revenue | CN¥502.73m |
Gross Profit | CN¥226.07m |
Other Expenses | CN¥90.96m |
Earnings | CN¥135.11m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 29, 2024
Earnings per share (EPS) | 2.21 |
Gross Margin | 31.02% |
Net Profit Margin | 18.54% |
Debt/Equity Ratio | 0.3% |
How did 301257 perform over the long term?
See historical performance and comparison